| |
NGS is unlocking new possibilities in discovery and diagnostics, but few solutions can keep up with its needs. Access our toolkit to discover how out-of-the-box NGS empowers innovators to hit the ground running. Learn more.
|
|
Today's Big NewsJul 12, 2023 |
|
Sciensus offers the infrastructure, regulatory expertise and experience to navigate the complexities of international distribution and get your rare drugs to hard-to-reach patients. Learn more.
|
|
| By Nick Paul Taylor Avrobio is tearing up its plans. Rather than push ahead with work on a trio of gene therapies, the biotech has decided to stop development, lay off half its staff and seek buyers interested in its remaining assets. |
|
|
|
By Nick Paul Taylor Theratechnologies’ R&D staff are bearing the brunt of its commercial failings. With sales falling short of expectations, the biotech is reducing its R&D head count and narrowing its focus to lower outgoings. |
By Max Bayer Liminal BioSciences is following through with a premium buyout offer from its top shareholder, Structured Alpha LP. The asset-manager-led fund is buying the company's outstanding common shares at $8.50 per share, a 135% premium compared to the price before the deal was first announced. |
Sponsored by Clinical Enrollment Using behavioral data science and social algorithms, this boutique biotech agency creates therapeutic-specific and patient-centric content to bypass traditional channels and speak directly to patients. |
By James Waldron South Korea and Switzerland-based OSR Holdings is the latest biotech business to choose a merger with a special purpose acquisition company as a way to hop onto the public markets. |
Sponsored by OneStudyTeam Hear why sponsors should equip sites with technology that makes securely capturing pre-screening, recruitment, and enrollment data easier. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Annalee Armstrong Fierce Biotech is once again seeking your nominations for the best, most exciting and innovative private biotechs. |
By Conor Hale Illumina said it will appeal a 432 million euro fine levied by the European Commission for jumping the regulatory gun two years ago, when the DNA sequencing giant closed its multibillion-dollar acquisition of the multicancer blood test maker Grail. |
By Nick Paul Taylor Biogen is the big loser in an annual review of biopharma brand values. After a year in which lawmakers accused Biogen of “inappropriately” collaborating with the FDA and setting an “unjustifiably high price,” the biotech’s brand value slumped 39%, sending it down a leader board topped by Johnson & Johnson. |
By Conor Hale The recall spans more than 21,000 Megadyne return electrode pads distributed to hospitals and surgery centers over a two-year period. |
By Fraiser Kansteiner Moderna has lodged two new lawsuits at the High Court in Dublin, Ireland, and the Brussels Commercial Court in Belgium, Juve Patent first reported. This adds to a complex web of ongoing mRNA patent litigation. |
By Frank Diamond Prior research about drug shortages looked at frequency and intensity. New Rand research looks at how they affect consumers. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss new HIV therapies, plus Humira's new biosimilar, foreign pharmaceutical investments, and the rest of the week's headlines. |
|
|---|
|
|
| ResearchThe right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookThis eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookTake a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
